Screening Study To Identify Patients At Risk For Cardiac Amyloidosis
Posted Date: Feb 1, 2021
- Investigator: Robert O'donnell
- Specialties: Cardiology, Cardiovascular Disease
- Type of Study: Observational/Survey
Transthyretin amyloidosis (ATTR) is caused by misfolded transthyretin proteins that can deposit in different organs in the body. When transthyretin fibrils deposit in the heart, an infiltrative cardiomyopathy can develop. Cardiac amyloidosis (CA) secondary to ATTR is thought to frequently go undiagnosed or misdiagnosed and is associated with increased mortality. Treatment of ATTR is a rapidly evolving area in therapeutics. Therefore, an emphasis has been placed on the development of techniques to identify patients with CA-ATTR. The purpose of this study is to use validate and then implement a bioinformatics tool to identify patients at risk for cardiac amyloidosis.
Adult Patients With Known Or Suspected Transthyretin Amyloidosis.
Amyloidosis, Infiltrative Heart Disease, Attr
For More Information: